Pharmaceutical Business Review reports that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Forxiga (dapagliflozin) to treat adults with type 1 diabetes. TrialSite News has covered this drug in...
Zenopa reports commercial sponsor AstraZeneca experienced good news from their Phase III DECLARE-TIMI 58 trial for Farxiga (dapagliflozin), which involves 17,000 adults in 33 countries with type-2 diabetes and cardiovascular disease, or multiple cardiovascular risk...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
